Evidence map›Paper›PMID 41704163›Full record

ArticleJournal of cachexia, sarcopenia and muscle2026

Cancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.

Yann Colardelle, Melanie Daligault, Julien Grosjean, Stefan J Darmoni, Badisse Dahamna, Richard B Weiskopf, Vickie E Baracos

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cancer cachexia: a caregiver and advocate perspective.Current opinion in supportive and palliative care · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yann ColardelleSociety on Sarcopenia, Cachexia and Wasting Disorders (SCWD), Duluth, Georgia, USA.
Melanie DaligaultUniv Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Rouen, France.
Julien GrosjeanUniv Rouen Normandie, RecSan, AIMS Lab, Digital Health Department, CHU Rouen, Rouen, France.
Stefan J DarmoniUniv Rouen Normandie, RecSan, AIMS Lab, Digital Health Department, CHU Rouen, Rouen, France.
Badisse DahamnaUniv Rouen Normandie, RecSan, AIMS Lab, Digital Health Department, CHU Rouen, Rouen, France.
Richard B WeiskopfUniversity of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-1749-1726
Vickie E BaracosUniversity of Alberta, Edmonton, Canada.

Funding

Society on Sarcopenia, Cachexia and Wasting Disorders
6 · The paper itself

Abstract

backgroundWidespread lack of awareness and limited real-world prevalence evidence have impeded cachexia care and research. We hypothesized that healthcare professionals may identify the term cachexia, leading to International Classification of Diseases (ICD) coding for this term, with or without records of body weight loss for diagnosing cancer cachexia, and that frequently, ICD coding does not accurately reflect weight data.

methodsWe assessed cachexia prevalence in patients diagnosed with cancer, using the Clinical Data Warehouse of a French hospital containing two types of real-world digitized data: (a) 'structured': coded diagnoses and electronic records; (b) 'unstructured': uncoded clinical narratives/reports: discharge summaries, procedure results, letters. Two sequential searches covering 2018-2023 (1) determined the prevalence of cachexia in all patients with a diagnosis of cancer using ICD-10 code R64 (cachexia), electronic records of body weight and unstructured narrative data; and (2) examined data of cancers of high-prevalence cachexia: colorectal, pancreatic and bronchial/lung cancers, determining (a) prevalence of cachexia by these criteria; (b) extent to which a diagnosis of cachexia was supported by weight loss data; and (c) extent to which the diagnosis of cachexia was not made despite objective weight data indicating its presence.

resultsA total of 76 547 of 737 906 patients had cancer of any primary type; 1856 (2.42%) of these had a cachexia diagnosis: 620 identified by ICD code, 1507 by unstructured data, including 271 by both. Of 6946 patients with colorectal, pancreatic or bronchial/lung cancer, 2033 patients (29.3%) were identified with cachexia by structured and/or unstructured data; both approaches were required to discover cachexia cases. From structured data an ICD-R64 search found only 254 patients described by the term cachexia, of which 127 had weight data supporting the diagnosis in the electronic medical record. An additional 1340 patients with BMI < 20 kg/m

conclusions(1) Standard ICD code-searching underestimated cachexia prevalence in all patients and those with high-prevalence-cachexia cancers; (2) Many cachexia cases were not diagnosed, although data indicated its presence; (3) Many cachexia cases diagnosed by judgement were not supported by data; (4) Increasing provider awareness of cancer cachexia definitions would likely improve cachexia care and research.

Indexed as

CachexiaMedical RecordsNeoplasmsAgedFemaleHumansMaleMiddle AgedPrevalenceTertiary Care CenterscachexiacancerdiagnosisICD codingprevalence

Identifiers

PMID41704163
PMCPMC12914221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.